Perioperative plasma concentrations of tumor necrosis factor-α and interleukin-6 in infected patients

Critical Care Medicine

Volumn 24, Issue 3, 1996, Pages 423-428

  Tang, Gau Jun ^a   Kuo, Cheng Deng ^a   Yen, Tzu Chen ^a   Kuo, H Sung ^a   Chan, Kwok Hon ^a   Yien, Huey Wen ^a   Lee, Tak Yu ^a  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

APACHE II score; critical illness; cytokines; infection; interleukin 6; sepsis; surgery; tumor necrosis factor

Indexed keywords

INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA;

ABDOMINAL INFECTION; ADULT; AGED; ARTICLE; BLOOD LEVEL; CLINICAL ARTICLE; CRITICAL ILLNESS; FEMALE; HUMAN; MALE; PERIOPERATIVE PERIOD; PRIORITY JOURNAL; SEPSIS; SURGERY;

ADULT; AGED; ANALYSIS OF VARIANCE; BACTERIAL INFECTIONS; FEMALE; HUMANS; IMMUNORADIOMETRIC ASSAY; INTERLEUKIN-6; MALE; MIDDLE AGED; SEPSIS; SURGICAL PROCEDURES, OPERATIVE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0029869201     PISSN: 00903493     EISSN: None     Source Type: Journal    
DOI: 10.1097/00003246-199603000-00010     Document Type: Article

References (26)

1. Tracey KJ, Beutler B, Lowry SF, et al: Shock and tissue injury by recombinant human cachectin. Science 1986; 234: 470-474
2. Shalaby MR, Aggarwal BB, Rinderknecht E, et al: Activation of human polymorphonuclear neutrophil functions by interferon-γ and tumor necrosis factors. J Immunol 1985; 135: 2069-2073
3. Nawroth PP, Stern DM: Modulation of endotholial cell homeostatic properties by tumor necrosis factor. J Exp Med 1986; 163:740-745
4. Horvath CJ, Ferro TJ, Jesmok G, et al: Recombinant tumor necrosis factor increases pulmonary vascular permeability independent of neutrophils. Proc Natl Acad Sci USA 1988; 85:9219-9223
5. Le J, Vilcek J: Interleukin-6: A multifunctional cytokine regulation immune reaction and the acute phase protein response. Lab Invest 1989; 61:588-602
6. Hack CE, De Groot ER, Felt-Bersma RJF, et al: Increased plasma levels of interleukin-6 in sepsis. Blood 1989; 74: 1704-1710
7. Damas P, Ledoux D, Nys M, et al: Cytokine serum level during severe sepsis in human IL-6 as a marker of severity. Ann Surg 1992; 215:356-362
8. Dofferhoff AM, Bom VJJ, de Vries-Hopers HG, et al: Patterns of cytokines, plasma endotoxin, plasminogen activator, and acute-phase proteins during the treatment of severe sepsis in humans. Crit Care Med 1992; 20:185-192
9. Members of the American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference Committee: American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 1992; 20:864-874
10. Knaus WA, Draper EA, Wagner DP, et al: APACHE II: A severity of disease classification system. Crit Care Med 1985; 13:818-829
11. Beutler B, Cerami A: Cachectin: More than a tumor necrosis factor. N Engl J Med 1987; 316:379-385
12. Offner F, Philippe J, Vogelaers D, et al: Serum tumor necrosis factor levels in patients with infectious disease and septic shock. J Lab Clin Med 1990; 116: 100-105
13. Fugger R, Zadrobilek E, Gotzinger P, et al: Perioperative TNF alpha and IL-6 concentrations correlate with septic state, organ function, and APACHE II scores in intra-abdominal infection. Eur J Surg 1993; 159:525-529
14. Fisher CJ Jr, Opal SM, Dhainaut JF, et al: Influence of an anti-tumor necrosis factor monoclonal antibody on cytokine levels in patients with sepsis. Crit Care Med 1993; 21:318-327
15. Hamilton G, Hofbauer S, Hamilton B: Endotoxin, TNF-alpha, Interleukin-6 and parameters of the cellular immune system in patients with intraabdominal sepsis. Scand J Infect Dis 1992; 24: 361-368
16. Michie HR, Monogue KR, Spriggs DR: Detection of circulating tumor necrosis factor after endotoxin administration. N Engl J Med 1988; 318:1481-1486
17. Stephens KE, Ishizaka A, Larrick JW, et al: Tumor necrosis factor causes increased permeability and edema. Comparison to septic acute lung injury. Am Rev Respir Dis 1988; 137:1364-1370
18. Tracey KJ, Fong Y, Hesse DG, et al: Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia. Nature 1987; 330:662-664
19. Hinshaw LB, Tekamp-Olson P, Chang AC, et al: Survival of primates in LD100 septic shock following therapy with antibody to tumor necrosis factor (TNF alpha). Circ Shock 1990; 30:279-292
20. Van Snick J: Interleukin 6: An overview. Annu Rev Immunol 1990; 8:253-278
21. Cruickshank AM, Fraser WD, Burns HJG, et al: Response of serum interleukin-6 in patients undergoing elective surgery of varying severity. Clin Sci 1990; 79:161-165
22. Michie HR, Monogue KR, Spriggs DR, et al: Detection of circulating tumor necrosis factor after endotoxin administration. N Engl J Med 1988; 318:1481-1486
23. Suffredini AF, Fromm RE, Parker MM, et al: The cardiovascular response of normal humans to the administration of endotoxin. N Engl J Med 1989; 321: 280-287
24. Joris J, Cigarini I, Legrand M, et al: Metabolic and respiratory changes after cholecystectomy performed via laparotomy or laparoscopy. Br J Anaesth 1992; 69:341-345
25. Michie HR, Wilmore DW: Sepsis, signals, and surgical sequelae (a hypothesis). Arch Surg 1990; 125:531-536
26. Ayala A, Kisala JM, Felt JA, et al: Does endotoxin tolerance prevent the release of inflammatory monokines (interleukin 1, interleukin 6, or tumor necrosis factor) during sepsis? Arch Surg 1992; 127:191-197